Tong Mancy, Chen Qi, James Joanna L, Stone Peter R, Chamley Lawrence W
Department of Obstetrics and Gynaecology, School of Medicine, The University of Auckland, Auckland, New Zealand.
Front Endocrinol (Lausanne). 2017 Jul 24;8:174. doi: 10.3389/fendo.2017.00174. eCollection 2017.
BACKGROUND/OBJECTIVES: Preeclampsia is a life-threatening hypertensive disease affecting 3-5% of pregnancies. While the pathogenesis of preeclampsia remains unclear, it is known that placenta-derived factors trigger the disease by activating maternal endothelial cells prior to the onset of clinical symptoms. Extracellular vesicles (EVs) of different sizes extruded by the placenta may be one factor. The truncated/secreted form of Flt-1 (sFlt-1) has also been implicated in the pathogenesis of preeclampsia. We investigated whether placental EV production is altered in preeclampsia such that they induce endothelial cell activation, and whether (s)Flt-1 is involved.
Macro-, micro-, and nano-vesicles were collected from normal and preeclamptic (PE) placental explants, and separated by differential centrifugation. The number and size of micro- and nano-vesicles was measured by nanoparticle tracking analysis and their ability to activate endothelial cells was quantified by endothelial cell intercellular adhesion molecule 1 expression and monocyte adhesion. The levels of Flt-1 were measured by western blots and ELISA.
PE placentae extruded significantly more micro- and nano-vesicles than control placentae and the extruded micro-vesicles were larger than those from control placentae. Micro- and nano-vesicles from both first trimester and term human placentae carried Flt-1 and levels were significantly increased in EVs from severe, but not mild, PE compared to normotensive placentae. All fractions of EVs from PE placentae activated endothelial cells, and for micro- and nano-vesicles, activation was reduced in the presence of exogenous vascular endothelial growth factor (VEGF), a Flt-1 neutralizing antibody, or by pre-treatment with VEGF. While EV-bound VEGF constituted over 20% of the total detected VEGF secreted by PE and normotensive placentae, EV-bound Flt-1 did not significantly contribute to the total level of sFlt-1/Flt-1 released by human third trimester placentae.
Micro- and nano-vesicles extruded by human placentae carry Flt-1 across gestation and in severe preeclampsia, the levels of vesicle-bound Flt-1 are upregulated. All fractions of PE placental EVs activated endothelial cells and for micro- and nano-vesicles, this was in part due to the ability of EV-bound Flt-1 to sequester VEGF. That placental EVs can activate endothelial cells supports the contention that EVs are one placental toxin contributing to the pathogenesis of preeclampsia.
背景/目的:子痫前期是一种危及生命的高血压疾病,影响3%-5%的妊娠。虽然子痫前期的发病机制尚不清楚,但已知胎盘衍生因子在临床症状出现之前通过激活母体内皮细胞引发该疾病。胎盘挤出的不同大小的细胞外囊泡(EVs)可能是一个因素。Flt-1的截短/分泌形式(sFlt-1)也与子痫前期的发病机制有关。我们研究了子痫前期中胎盘EV的产生是否发生改变,从而诱导内皮细胞活化,以及(s)Flt-1是否参与其中。
从正常和子痫前期(PE)胎盘外植体中收集大、中、小囊泡,并通过差速离心进行分离。通过纳米颗粒跟踪分析测量中、小囊泡的数量和大小,并通过内皮细胞细胞间黏附分子1表达和单核细胞黏附来量化它们激活内皮细胞的能力。通过蛋白质免疫印迹法和酶联免疫吸附测定法测量Flt-1的水平。
与对照胎盘相比,PE胎盘挤出的中、小囊泡明显更多,且挤出的中囊泡比对照胎盘的更大。来自孕早期和足月人胎盘的中、小囊泡都携带Flt-1,与血压正常的胎盘相比,重度(而非轻度)PE的EV中Flt-1水平显著升高。来自PE胎盘的所有EV组分均能激活内皮细胞,对于中、小囊泡,在外源血管内皮生长因子(VEGF)、Flt-1中和抗体存在的情况下,或经VEGF预处理后,激活作用减弱。虽然与EV结合的VEGF占PE和血压正常胎盘分泌的总检测VEGF的20%以上,但与EV结合的Flt-1对人妊娠晚期胎盘释放的sFlt-1/Flt-1总水平没有显著贡献。
人胎盘挤出的中、小囊泡在整个妊娠期都携带Flt-1,在重度子痫前期,与囊泡结合的Flt-1水平上调。PE胎盘EV的所有组分均能激活内皮细胞,对于中、小囊泡,部分原因是与EV结合的Flt-1能够隔离VEGF。胎盘EV能够激活内皮细胞支持了EV是导致子痫前期发病机制的一种胎盘毒素这一观点。